The largest database of trusted experimental protocols

Pmirglo dual luciferase vector

Manufactured by GenePharma
Sourced in China

The PmirGLO Dual-Luciferase Vector is a tool used for gene expression analysis. It contains two luciferase reporter genes, which allow for the simultaneous measurement of two different luciferase activities in the same sample. This vector can be used to study the regulation of gene expression or to evaluate the activity of regulatory sequences.

Automatically generated - may contain errors

35 protocols using pmirglo dual luciferase vector

1

Evaluating mmu_circ_0005019-miR-499-5p Interaction

Check if the same lab product or an alternative is used in the 5 most similar protocols
To evaluate the mmu_circ_0005019 and miR-499-5p interaction by luciferase reporter assay, the miR-499-5p binding sites of mmu_circ_0005019 were inserted into the pmirGLO Dual-Luciferase vector (GenePharma). The reconstituted plasmid was named mmu_circ_0005019-WT. The miR-499-5p target site mutations were introduced and inserted into the pmirGLO Dual-Luciferase vector (GenePharma), which was named mmu_circ_0005019-MU. The plasmid construction was performed by GenePharma Corporation. HL-1 cells were seeded into 24-well plates (2 × 104 cells per well) in triplicate for each group. After overnight incubation, cells were co-transfected with reconstituted plasmid and miR-499-5p mimics. Firefly and Renilla luciferase activities were measured 48 h after transfection using the Dual-Luciferase Assay System (Promega, Madison, WI, USA). The relative luciferase activity was calculated using Firefly/Renilla luciferase activity.
+ Open protocol
+ Expand
2

Dual Luciferase Reporter Assay for miR-145 Targets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Wild-type and mutant KLF4 (with mutated miR-145 binding sites) were cloned into a pmirGLO dual luciferase vector (GenePharma) to construct dual luciferase reporter plasmids. HEK293T cells were cotransfected with wild-type pmirGLO-KLF4 (or mutant) and miR-145 mimics (or a negative control) using Lipofectamine 2000. Similarly, dual luciferase reporter plasmids containing TGFBR2-WT and TGFBR2-Mut were constructed. HEK293T cells were cotransfected with either miR-145 mimics/inhibitor or their corresponding empty vectors and luciferase reporter plasmids using Lipofectamine 2000. Luciferase activity was analyzed using a dual luciferase reporter kit (Promega, USA) after 48 h of transfection. Renilla luciferase activity was measured as a transfection efficiency control.
+ Open protocol
+ Expand
3

Validating miR-103a-3p Binding Sites

Check if the same lab product or an alternative is used in the 5 most similar protocols
Potential miR-103a-3p binding sites of linc00152 and FEZF1 3′-UTR were predicted by bioinformatics tool Starbase (http://starbase.sysu.edu.cn/) and Target Scan (http://www.targetscan.org/). In brief, the fragment of linc00152 possessing the assumptive miR-103a-3p binding sites was cloned into a pmirGLO Dual-Luciferase Vector (Promega, Madison, WI, USA) to construct the reporter vector linc00152-wild-type (linc00152-Wt) (GenePharma, Shanghai, China). Analogously, the corresponding mutant of hypothetic miR-103a-3p binding sites was manufactured to form the reporter vector linc00152-mutated-types (linc00152-Mut) (GenePharma, Shanghai, China). The 3′-UTR fragment of FEZF1 gene and its mutant of the theoretical miR-103a-3p binding site were cloned into a pmirGLO Dual-Luciferase Vector to form the reporter vector FEZF1-3′-UTR-wild-type (FEZF1-3′-UTR-Wt) and FEZF1-3′-UTR-mutated-type (FEZF1-3′-UTR-Mut) (GenePharma, Shanghai,China), respectively. The pmirGLO vector(wild type fragments or mutated type fragments) and indicated miRNAs were transfected into HEK 293 T cells using Lipofectamine 3000. Relative luciferase activities were measured 48 h after transfection and firefly luciferase activity was normalized by renilla luciferase activity.
+ Open protocol
+ Expand
4

miRNA-Target Gene Interaction Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
The predicted miR‐499a‐5p binding sequence in SCAMP1 and LMX1A 3' UTR sequence and their corresponding mutant sequence were cloned into pmirGLO Dual‐Luciferase Vector to construct luciferase reporter vector (SCAMP1‐Wt or ‐Mut and LMX1A‐3' UTR‐Wt or ‐Mut; GenePharma). HEK293T cells were seeded into a 96‐well plate and co‐transfected with the indicated vectors and miR‐499a‐5p agomir or its negative control respectively. Dual‐luciferase assay was performed 48 hours after transfection, the relative luciferase activity was normalized to Renilla luciferase activity and calculated by Dual‐Luciferase Reporter Assay System (Promega, Madison, WI).
+ Open protocol
+ Expand
5

Validating miR-155 Binding to TLR3 mRNA

Check if the same lab product or an alternative is used in the 5 most similar protocols
Binding sites for miR-155 in the TLR3 mRNA sequence were predicted using TargetScan Human 7.1 database. Constructs containing the wild-type (WT) or a mutant (MUT) 3′ UTR sequence of TLR3 mRNA were inserted into the pmiR-GLO dual-luciferase vector (GenePharma). HeLa cells were co-transfected with miR-155 mimics or mimic NC along with WT or MUT vectors using Lipofectamine 2000. Cells were collected 48 h after transfection and luciferase activity was detected using a dual-luciferase reporter assay system (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Renilla activity was calculated for normalization. Each experiment was performed in triplicate.
+ Open protocol
+ Expand
6

Validating miRNA-target Interactions

Check if the same lab product or an alternative is used in the 5 most similar protocols
StarBase predicted targeted binding sites for MALAT1 and miR-23b-3p and targeted binding sites for miR-23b-3p and α-synuclein. The miR-23b-3p and MALAT1 or α-synuclein 3′-UTR binding site and its mutated sequence were inserted into the pmirGLO dual luciferase vector (GenePharma, Shanghai, China). The constructed vector was cotransfected with miR-23b-3p mimic and its negative control (NC mimic) into cells using Lipofectamine 2000. Forty-eight hours after transfection, luciferase activity was detected using a dual luciferase reporter assay kit (Hanbio Biotechnology, Shanghai, China).
+ Open protocol
+ Expand
7

Decoding the LINC-PINT-miR-155 Interaction

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bioinformatics software Starbase 2.0 was used to analyze the complementary binding sites of LINC-PINT and miR-155-5p. In brief, the fragment of LINC-PINT possessing the assumptive miR-155-5p binding sites was cloned into a pmirGLO Dual-Luciferase Vector (GenePharma, Shanghai, China). MUT-LINC-PINT was constructed by conjugating sequence mutation of Linc-PINT, and a luciferase reporter vector without the mutation (WT-Linc-PINT) was constructed. Mut-LINC-PINT or WT-LINC-PINT were co-transfected with miR-155 mimics (5ʹ-UUAAUGCUAAUCGUGAUAGGGGUU-3ʹ), miR-155 inhibitor (5ʹ-AACCCCUAUCACGAUUAGCAUUAA-3ʹ), mimic NC (5ʹ-UUCUCCGAACGUGUCACGUTT-3ʹ) or inhibitor NC (5ʹ-CAGUACUUUUGUGUAGUACAA-3ʹ) into T24 and 5637 cells, respectively. After 48 h of culture, luciferase activity was detected with a luciferase activity detection kit. The expression level of miR-155 in BC tissues and normal tissues was determined according to the above qRT-PCR method. Meanwhile, qRT-PCR was used to detect the changes of miR-155 expression in T24 cells transfected with control, NC, and pcDNA-LINC-PINT.
+ Open protocol
+ Expand
8

Validation of miR-653 Targeting Pathway

Check if the same lab product or an alternative is used in the 5 most similar protocols
StarBase (http://starbase.sysu.edu.cn) online tool was used to predict the potential miRNAs that could bind to PLK1S1, while TargetScan (http://www.targetscan.org) was used to predict the potential downstream target of miR-653. Mutants within the miR-653 binding site were created using the QuikChange II Site Directed Mutagenesis kit (Agilent Technologies, Inc.). The wild-type (WT) and mutant (Mut) PLK1S1 or CXCR5 was sub-cloned into pmirGLO dual-luciferase vector (Shanghai GenePharma Co., Ltd.) to construct PLK1S1-WT/Mut or CXCR5-WT/Mut vectors. Subsequently, PLK1S1-WT/Mut or CXCR5-WT/Mut vectors were co-transfected with NC mimic, miR-653 mimic and miR-653 inhibitor into 293T cells using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Luciferase activity was evaluated using the Dual-Luciferase Reporter Analysis system (Promega Corporation), following incubation for 48 h. Firefly luciferase activity was normalized to Renilla (Promega Corporation) luciferase gene activity.
+ Open protocol
+ Expand
9

Dual-Luciferase Assay to Validate miR-142-3p Targeting

Check if the same lab product or an alternative is used in the 5 most similar protocols
The wild-type (WT) and mutant-type (MUT) sequences of the PIK3CG-3’-untranslated region (UTR) were synthesized by GenePharma (Shanghai, China) and inserted into the pmiR-GLO dual-luciferase vector. WT PIK3CG-3’-UTR and MUT PIK3CG-3’-UTR were employed to transfect 293 T cells that overexpressed miR-142-3p or its control with Lipofectamine 2000 (Invitrogen, USA). Renilla luciferase expression plasmids were transfected into cells as an endogenous control. Forty-eight hours later, we lysed the harvested cells with a lysis buffer (Promega, USA). Firefly and renilla luciferase activities were examined by the Dual-Luciferase Reporter Assay System (Promega, USA), following the manufacturer’s instructions [25 (link)].
+ Open protocol
+ Expand
10

Validation of miR-422a Targeting of PDK1 and PDK2

Check if the same lab product or an alternative is used in the 5 most similar protocols
The 3′-UTRs of PDK1 and PDK2 containing putative miR-422a target regions were cloned into a firefly luciferase reporter, the pmirGLO Dual-luciferase vector (GenePharma, China). In addition, the mutant miR-422a putative target regions were generated using the same approach. SGC7901 cells overexpressing miR-422a or its control were transfected with PDK1–3′-UTR-Wt, PDK1–3′-UTR-Mut, PDK2–3′-UTR-Wt or PDK2–3′-UTR-Mut, lysed 48 h after transfection and assayed using a Dual-Luciferase Reporter Assay System (E1910, Promega).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!